Company Profile
Lexicon Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- LXRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.04 USD (+0.74%)
Close
Last updated: September 17, 2026
840M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, LXRX closed up 0.74% at $2.04. No new same-company headline was identified in the current news window.
Company overview
Genetically Informed Drug Discovery
Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases.
Sotagliflozin Franchise
Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application targets adults with type 1 diabetes.
Hypertrophic Cardiomyopathy
The SONATA-HCM study evaluates sotagliflozin in hypertrophic cardiomyopathy. Lexicon also maintains development programs in neuropathic pain, obesity and metabolic disease.
Neuropathic-Pain and Metabolic Pipeline
Beyond sotagliflozin, Lexicon maintains discovery, preclinical and clinical candidates in neuropathic pain, obesity and other cardiometabolic disorders.
Future catalysts
- Completion of enrollment in SONATA-HCM around mid-2026.
- NDA resubmission for ZYNQUISTA around mid-2026.
- Topline SONATA-HCM results in the first quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Lexicon Pharmaceuticals (LXRX)?
Lexicon Pharmaceuticals (LXRX) most recently closed at 2.04 USD, a +0.74% move versus the previous session.
What is the market cap of Lexicon Pharmaceuticals (LXRX)?
Lexicon Pharmaceuticals currently has a market capitalization of 840M USD on BioPharmSignal.
What does Lexicon Pharmaceuticals do?
Genetically Informed Drug Discovery Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases. Sotagliflozin Franchise Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor. It is marketed as INPEFA for heart-failure-related indications, while the ZYNQUISTA application targets adults with...
On which exchange is LXRX stock listed?
Lexicon Pharmaceuticals (LXRX) is associated with NASDAQ, United States, Biopharma.
What is SONATA-HCM?
Completion of enrollment in SONATA-HCM around mid-2026.
Which conditions is Lexicon Pharmaceuticals targeting with SONATA-HCM?
Lexicon Pharmaceuticals is associated with metabolic disease, obesity, diabetes based on its company overview and current catalyst commentary.
How does Lexicon Pharmaceuticals describe recent progress with SONATA-HCM?
Completion of enrollment in SONATA-HCM around mid-2026.
What is Genetically?
Genetically Informed Drug Discovery Lexicon Pharmaceuticals uses human-genetic insights to discover and develop medicines for cardiometabolic and neurologic diseases.